Honokiol

Honokiol at a Glance

Honokiol is a biphenol neolignan (3’,5-diallyl-2,4’-dihydroxybiphenyl) and, alongside its positional isomer magnolol, one of the two principal bioactive markers of magnolia bark (Magnolia officinalis, houpo) — a remedy with a long history in Chinese and Kampo medicine for anxiety, low mood and digestive complaints. The two molecules are almost always discussed as a pair; they differ only in where the second hydroxyl and allyl groups sit on the biphenyl skeleton, yet that small difference gives honokiol its own pharmacology ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}.

The defining, compound-unique feature is that honokiol crosses the blood-brain barrier and distributes into brain tissue — the reason so much of its research is neurological (sleep, neuroprotection, mood) rather than confined to the periphery ^{22,4Reference 22Borgonetti V et al. · 2021A honokiol-enriched Magnolia officinalis Rehder & E.HView study →Reference 4Woodbury A et al. · 2013ReviewNeuro-modulating effects of honokiol: a reviewView study →}. In animal and cell studies the isolate is anxiolytic and sleep-promoting through the benzodiazepine site of the GABA-A receptor ^{2Reference 2Qu WM et al. · 2012AnimalHonokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in miceView study →}, neuroprotective in stroke and Alzheimer’s models ^{5,6,8Reference 5Liou KT et al. · 2003AnimalHonokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species productionView study →Reference 6Liou KT et al. · 2003AnimalHonokiol ameliorates cerebral infarction from ischemia-reperfusion injury in ratsView study →Reference 8Li Y et al. · 2024Systematic reviewNeolignans in Magnolia officinalis as natural anti-Alzheimer’s disease agents: A systematic reviewView study →}, antidepressant-like ^{10,11Reference 10Zhang B et al. · 2019AnimalAntidepressant-Like Effect and Mechanism of Action of Honokiol on the Mouse Lipopolysaccharide (LPS) Depression ModelView study →Reference 11Wang C et al. · 2018AnimalHonokiol Exerts Antidepressant Effects in Rats Exposed to Chronic Unpredictable Mild Stress by Regulating Brain Derived Neurotrophic Factor Level and Hypothalamic-Pituitary-Adrenal Axis ActivityView study →}, and a heavily studied anticancer molecule acting on multiple pathways (pro-apoptotic, anti-angiogenic, mTOR / STAT3 / EGFR signalling) ^{12,13,14Reference 12Fried LE · 2009Honokiol, a multifunctional antiangiogenic and antitumor agentView study →Reference 13Ong CP et al. · 2019ReviewHonokiol: A Review of Its Anticancer Potential and MechanismsView study →Reference 14Lee JS et al. · 2019Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathwayView study →}.

The honest caveat runs through all of it: the human evidence is thin. The best human data belong to the standardised magnolia-plus-Phellodendron blend Relora, not to isolated honokiol, and its own poor aqueous solubility and oral bioavailability are the main practical brake on translating the preclinical work ^{1,18Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →Reference 18Böhmdorfer M et al. · 2011In vitroIn vitro metabolism and disposition of honokiol in rat and human liversView study →}. Apparent toxicity is low ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}.

Honokiol vs. Magnolol

Honokiol and magnolol are positional (constitutional) isomers — the same molecular formula (C₁₈H₁₈O₂) and the same allyl-substituted biphenyl core, differing only in the position of the two hydroxyl groups on the rings. Magnolol is the symmetric 5,5’-diallyl-2,2’-dihydroxybiphenyl; honokiol is the asymmetric 3’,5-diallyl-2,4’-dihydroxybiphenyl, in which one hydroxyl sits para rather than ortho to the ring junction. That single change in geometry is enough to shift their behaviour: honokiol’s hydroxyls cannot form the same intramolecular arrangement as magnolol’s, which alters lipophilicity, membrane interaction and target binding ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}.

In practice the two overlap heavily — both potentiate GABA-A signalling, both are anti-inflammatory and antioxidant, and both are studied as anticancer agents — but they are not interchangeable. Honokiol is generally credited with the more prominent central-nervous-system and anticancer profile and is the more brain-penetrant of the pair, while magnolol is the more abundant marker in raw bark (roughly 2-11% versus honokiol’s ~1-5%) ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}. Bark extracts are typically standardised to the sum of the two, so an “isolated honokiol” claim and a “magnolia bark extract” claim are different exposures.

Blood-Brain Barrier Penetration

The property that most sets honokiol apart from the average plant phenol is that it reaches the brain. It is a small (266 Da), lipophilic molecule, and pharmacokinetic and imaging work show it crosses the blood-brain barrier and distributes into central tissue after systemic dosing — the mechanistic reason its neurological effects (sedation, neuroprotection, antidepressant activity, and activity against brain tumours) are plausible at all ^{22,4Reference 22Borgonetti V et al. · 2021A honokiol-enriched Magnolia officinalis Rehder & E.HView study →Reference 4Woodbury A et al. · 2013ReviewNeuro-modulating effects of honokiol: a reviewView study →}. This is the page’s load-bearing differentiator: a molecule that is anxiolytic in a dish is only interesting if it can get to neurons in a living animal, and honokiol can.

The corollary is that the CNS story is genuinely central, not a peripheral proxy. Honokiol has been formulated specifically to exploit or improve this — for example, honokiol liposomes have been targeted at brain glioma, and nano-honokiol preparations have been used to raise brain exposure in Alzheimer’s models ^{17,9Reference 17Liu S et al. · 2017Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain gliomaView study →Reference 9Qu C et al. · 2022AnimalNano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer’s disease via inhibiting neuropathology and modulating gut microbiotaView study →}. But brain penetration does not repair the underlying problem of low oral bioavailability: getting enough honokiol into the blood in the first place remains the limiting step, which is why much of the delivery research uses liposomes, nanoparticles or salt forms rather than plain oral honokiol ^{18,20Reference 18Böhmdorfer M et al. · 2011In vitroIn vitro metabolism and disposition of honokiol in rat and human liversView study →Reference 20He X et al. · 2022Improved Pharmaceutical Properties of Honokiol via Salification with Meglumine: an Exception to Oft-quoted ∆pKa RuleView study →}.

What It's Used For

Honokiol’s preclinical range is unusually broad for a single plant phenol, but the compound-page discipline applies throughout: nearly all of it is rodent and in-vitro work on the isolated molecule, and the marquee human evidence — for stress and sleep — belongs to a magnolia blend, not to isolated honokiol ^{1,2,12Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →Reference 2Qu WM et al. · 2012AnimalHonokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in miceView study →Reference 12Fried LE · 2009Honokiol, a multifunctional antiangiogenic and antitumor agentView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Human efficacy data are the blend (Relora), not the isolate, so isolate scores stay modest by design.

01Anxiolytic / SleepPromising46%Rodent isolate via GABA-A benzodiazepine site + CB1; human data on the blend ^{2,3,22Reference 2Qu WM et al. · 2012AnimalHonokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in miceView study →Reference 3Kuribara H et al. · 2000The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia barkView study →Reference 22Borgonetti V et al. · 2021A honokiol-enriched Magnolia officinalis Rehder & E.HView study →}

02AnticancerShaky42%Large multi-pathway preclinical body (apoptosis, anti-angiogenesis, mTOR/STAT3); no isolate human trials ^{12,13,14,15,16Reference 12Fried LE · 2009Honokiol, a multifunctional antiangiogenic and antitumor agentView study →Reference 13Ong CP et al. · 2019ReviewHonokiol: A Review of Its Anticancer Potential and MechanismsView study →Reference 14Lee JS et al. · 2019Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathwayView study →Reference 15Zhang Y et al. · 2014Downregulation of STAT3 and activation of MAPK are involved in the induction of apoptosis by HNK in glioblastoma cell line U87View study →Reference 16Mottaghi S · 2022ReviewNatural Lignans Honokiol and Magnolol as Potential Anticarcinogenic and Anticancer AgentsView study →}

03NeuroprotectionShaky40%Rodent stroke + Alzheimer’s models; anti-oxidant / anti-inflammatory ^{5,6,8,9Reference 5Liou KT et al. · 2003AnimalHonokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species productionView study →Reference 6Liou KT et al. · 2003AnimalHonokiol ameliorates cerebral infarction from ischemia-reperfusion injury in ratsView study →Reference 8Li Y et al. · 2024Systematic reviewNeolignans in Magnolia officinalis as natural anti-Alzheimer’s disease agents: A systematic reviewView study →Reference 9Qu C et al. · 2022AnimalNano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer’s disease via inhibiting neuropathology and modulating gut microbiotaView study →}

04AntidepressantShaky34%Rodent LPS and chronic-stress models; BDNF, neuroinflammation ^{10,11Reference 10Zhang B et al. · 2019AnimalAntidepressant-Like Effect and Mechanism of Action of Honokiol on the Mouse Lipopolysaccharide (LPS) Depression ModelView study →Reference 11Wang C et al. · 2018AnimalHonokiol Exerts Antidepressant Effects in Rats Exposed to Chronic Unpredictable Mild Stress by Regulating Brain Derived Neurotrophic Factor Level and Hypothalamic-Pituitary-Adrenal Axis ActivityView study →}

05Anti-InflammatoryShaky32%Neutrophil ROS suppression; NF-κB; mechanistic in-vitro/animal ^{7Reference 7Liou KT et al. · 2003The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species productionView study →}

06CardioprotectiveShaky28%Rodent post-infarction heart-failure model; mitochondrial ROS ^{21Reference 21Liu J et al. · 2022Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species InhibitionView study →}

How Honokiol Works

Honokiol does not act through one receptor; several parallel actions recur across its effects, unified by an anti-oxidant / anti-excitatory / pro-apoptotic-in-tumours theme.

GABA-A Benzodiazepine Site

Honokiol potentiates GABA-A signalling at the benzodiazepine site; its non-rapid-eye-movement- sleep promotion is abolished by the benzodiazepine-site antagonist flumazenil, placing it at the same allosteric site as classical anxiolytics but without their motor/amnesic burden in animals ^{2,3Reference 2Qu WM et al. · 2012AnimalHonokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in miceView study →Reference 3Kuribara H et al. · 2000The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia barkView study →}.

Endocannabinoid (CB1) Modulation

A honokiol-enriched bark extract’s anxiolytic-like effect involved CB1 receptor modulation, indicating a second calming route beyond GABA-A ^{22Reference 22Borgonetti V et al. · 2021A honokiol-enriched Magnolia officinalis Rehder & E.HView study →}.

Anti-Oxidant & Anti-Inflammatory Action

Honokiol scavenges reactive oxygen species and suppresses the neutrophil respiratory burst and NF-κB-driven inflammation ^{7,13Reference 7Liou KT et al. · 2003The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species productionView study →Reference 13Ong CP et al. · 2019ReviewHonokiol: A Review of Its Anticancer Potential and MechanismsView study →}. This single action plausibly underlies its neuroprotection in stroke, its Alzheimer’s-model benefit, and its cardioprotection ^{5,8,21Reference 5Liou KT et al. · 2003AnimalHonokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species productionView study →Reference 8Li Y et al. · 2024Systematic reviewNeolignans in Magnolia officinalis as natural anti-Alzheimer’s disease agents: A systematic reviewView study →Reference 21Liu J et al. · 2022Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species InhibitionView study →}.

Pro-Apoptotic & Anti-Angiogenic Signalling

In tumour cells honokiol shifts the balance toward apoptosis and blocks new blood-vessel formation, converging on mTOR (AMPK/mTOR), STAT3/MAPK, and EGFR/NF-κB signalling to suppress proliferation, migration and invasion ^{12,14,15,16Reference 12Fried LE · 2009Honokiol, a multifunctional antiangiogenic and antitumor agentView study →Reference 14Lee JS et al. · 2019Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathwayView study →Reference 15Zhang Y et al. · 2014Downregulation of STAT3 and activation of MAPK are involved in the induction of apoptosis by HNK in glioblastoma cell line U87View study →Reference 16Mottaghi S · 2022ReviewNatural Lignans Honokiol and Magnolol as Potential Anticarcinogenic and Anticancer AgentsView study →}.

A Unifying Interpretation

Most of honokiol’s repertoire collapses into two intertwined themes made accessible by one enabling property. The enabling property is brain penetration — a small lipophilic biphenol that reaches neurons ^{22,4Reference 22Borgonetti V et al. · 2021A honokiol-enriched Magnolia officinalis Rehder & E.HView study →Reference 4Woodbury A et al. · 2013ReviewNeuro-modulating effects of honokiol: a reviewView study →}. On top of that sit (1) a calming, excitability-lowering action through the GABA-A benzodiazepine site and CB1 modulation, explaining the anxiolytic, sleep and (with anti- neuroinflammation) antidepressant signals ^{2,22,11Reference 2Qu WM et al. · 2012AnimalHonokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in miceView study →Reference 22Borgonetti V et al. · 2021A honokiol-enriched Magnolia officinalis Rehder & E.HView study →Reference 11Wang C et al. · 2018AnimalHonokiol Exerts Antidepressant Effects in Rats Exposed to Chronic Unpredictable Mild Stress by Regulating Brain Derived Neurotrophic Factor Level and Hypothalamic-Pituitary-Adrenal Axis ActivityView study →}; and (2) a tissue-protective / pro-apoptotic redox action — scavenging reactive oxygen species and blocking NF-κB in healthy tissue, while tipping tumour cells into apoptosis via mTOR/STAT3 — which ties the neuroprotection, cardioprotection and anticancer work into one mechanism family ^{7,12,14,21Reference 7Liou KT et al. · 2003The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species productionView study →Reference 12Fried LE · 2009Honokiol, a multifunctional antiangiogenic and antitumor agentView study →Reference 14Lee JS et al. · 2019Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathwayView study →Reference 21Liu J et al. · 2022Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species InhibitionView study →}. What the tidy mechanism story cannot fix is delivery: the whole picture is preclinical, on the isolate, and gated by poor oral bioavailability ^{1,18Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →Reference 18Böhmdorfer M et al. · 2011In vitroIn vitro metabolism and disposition of honokiol in rat and human liversView study →}.

Isolate vs. Plant Studies

This distinction is central to reading honokiol honestly, and the two evidence bases diverge.

Evidence for the Isolate

The mechanistic and behavioural work is overwhelmingly the isolated molecule in rodents and cells: the GABA-A/flumazenil sleep study ^{2Reference 2Qu WM et al. · 2012AnimalHonokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in miceView study →}, the anxiolytic characterisation ^{3Reference 3Kuribara H et al. · 2000The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia barkView study →}, the stroke-model neuroprotection ^{5,6Reference 5Liou KT et al. · 2003AnimalHonokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species productionView study →Reference 6Liou KT et al. · 2003AnimalHonokiol ameliorates cerebral infarction from ischemia-reperfusion injury in ratsView study →}, the antidepressant models ^{10,11Reference 10Zhang B et al. · 2019AnimalAntidepressant-Like Effect and Mechanism of Action of Honokiol on the Mouse Lipopolysaccharide (LPS) Depression ModelView study →Reference 11Wang C et al. · 2018AnimalHonokiol Exerts Antidepressant Effects in Rats Exposed to Chronic Unpredictable Mild Stress by Regulating Brain Derived Neurotrophic Factor Level and Hypothalamic-Pituitary-Adrenal Axis ActivityView study →}, and the large anticancer mechanism body ^{12,14,15Reference 12Fried LE · 2009Honokiol, a multifunctional antiangiogenic and antitumor agentView study →Reference 14Lee JS et al. · 2019Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathwayView study →Reference 15Zhang Y et al. · 2014Downregulation of STAT3 and activation of MAPK are involved in the induction of apoptosis by HNK in glioblastoma cell line U87View study →}. As a preclinical mechanism base for the isolate, this is a genuine strength.

Evidence for Plant Extracts & Blends

The human evidence, by contrast, is not isolated honokiol. The controlled human data on stress/anxiety are for the standardised Magnolia officinalis + Phellodendron amurense blend (Relora), so those findings belong to the blend, not the molecule ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}. Several neurological “honokiol” results also use honokiol-enriched extracts or engineered nano/liposomal preparations rather than plain oral honokiol ^{22,9,17Reference 22Borgonetti V et al. · 2021A honokiol-enriched Magnolia officinalis Rehder & E.HView study →Reference 9Qu C et al. · 2022AnimalNano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer’s disease via inhibiting neuropathology and modulating gut microbiotaView study →Reference 17Liu S et al. · 2017Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain gliomaView study →}. The correct framing: strong isolate mechanism + meaningful human data for a blend + little direct human isolate efficacy — these are not interchangeable.

Prevalence in Nature

Honokiol is a magnolia molecule. It occurs chiefly in the bark of Magnolia officinalis (houpo) and related species (M. obovata, M. grandiflora, M. dealbata), alongside its isomer magnolol and the related neolignan obovatol ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}. In raw M. officinalis bark it is present at roughly 1-5% of dry weight, with magnolol usually the more abundant of the two (~2-11%); the ratio shifts markedly with species, geographic provenance, plant part and extraction method, and commercial extracts are standardised to concentrations far above the raw bark ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}. It is also reported from magnolia seed cones and flower tissue. It is not a widely distributed plant phenol in the way many flavonoids are — its occurrence is essentially confined to Magnolia and closely related genera, which is part of why magnolia bark is its defining source ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}.

Major Natural Sources

Source	Plant part	Reported honokiol content
Magnolia (Magnolia officinalis)	dried bark	~1-5% dry weight
Houpu magnolia (Magnolia obovata)	bark	present (marker neolignan)
Southern magnolia (Magnolia grandiflora)	bark / seed cones	present

These are figures for the bark, not the whole plant, and vary with species, provenance and method; extracts are standardised much higher ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}.

Discovery & Synthesis

Honokiol has long been known as one of the two marker neolignans of magnolia (houpo) bark, isolated and characterised alongside magnolol as chemists worked out the actives of a traditional East Asian bark drug; the name traces to the Japanese/Chinese common name for magnolia bark ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}. As a biphenol neolignan it is a biaryl coupling of two allyl-phenol (chavicol-type) units, and total syntheses build the molecule by forming that central biaryl bond (e.g. via metal-catalysed cross-coupling) and installing the allyl and hydroxyl groups regioselectively — the asymmetric substitution pattern being what distinguishes it from the symmetric magnolol.

Commercially, honokiol is obtained overwhelmingly by extraction and purification from magnolia bark rather than by total synthesis; the practical challenge is not making it but formulating a poorly water-soluble molecule — hence the liposome, nanoparticle and salt-form (e.g. meglumine salification) work aimed at raising its solubility and exposure ^{17,20Reference 17Liu S et al. · 2017Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain gliomaView study →Reference 20He X et al. · 2022Improved Pharmaceutical Properties of Honokiol via Salification with Meglumine: an Exception to Oft-quoted ∆pKa RuleView study →}.

Patents: not yet researched.

Toxicity & Safety

Honokiol’s apparent toxicity is low. A dedicated safety-and-toxicology review of magnolol and honokiol found no major toxicity signal at the exposures studied, consistent with magnolia bark’s long history of traditional and dietary-supplement use ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}. The badge is low on that basis — but with two honest qualifiers: comprehensive long-term human safety data for the isolate are limited, and the molecule’s poor oral bioavailability means ordinary oral exposure is modest ^{1,18Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →Reference 18Böhmdorfer M et al. · 2011In vitroIn vitro metabolism and disposition of honokiol in rat and human liversView study →}.

The plausible cautions are pharmacological rather than toxicological. As a molecule that potentiates GABA-A signalling at the benzodiazepine site, honokiol could in principle add to the effects of alcohol, benzodiazepines and other CNS depressants — a mechanism-based, not well-quantified, interaction ^{2Reference 2Qu WM et al. · 2012AnimalHonokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in miceView study →}. Its anti-inflammatory / anti-platelet-adjacent and anti-angiogenic activity also raises a theoretical additive bleeding-risk concern with anticoagulant and antiplatelet drugs, though this is extrapolated from mechanism rather than documented in human interaction studies ^{12Reference 12Fried LE · 2009Honokiol, a multifunctional antiangiogenic and antitumor agentView study →}. Honokiol is metabolised largely by glucuronidation (and sulfation), so it competes for UDP-glucuronosyltransferase capacity rather than heavily engaging cytochrome-P450 oxidation, which shapes its likely interaction profile ^{18,19Reference 18Böhmdorfer M et al. · 2011In vitroIn vitro metabolism and disposition of honokiol in rat and human liversView study →Reference 19Jeong HU et al. · 2016AnimalComparative metabolism of honokiol in mouse, rat, dog, monkey, and human hepatocytesView study →}.

Pregnancy/lactation is a per-herb / per-supplement decision and is not adjudicated on this molecule page; dedicated human reproductive-safety data for isolated honokiol are limited, and no isolate- specific verdict is issued here.

Safety at a Glance

✅ Low / no toxicity

• Apparent toxicity is low. A safety/toxicology review of magnolol and honokiol found no major toxicity signal at studied exposures, matching magnolia bark’s long use history ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}.
• Additive sedation, in principle. As a GABA-A benzodiazepine-site potentiator, honokiol could compound alcohol, benzodiazepines and other CNS depressants — a mechanism-based, poorly-quantified interaction ^{2Reference 2Qu WM et al. · 2012AnimalHonokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in miceView study →}.
• Theoretical bleeding-risk stacking. Its anti-inflammatory / anti-angiogenic activity is a reason for caution alongside anticoagulant or antiplatelet drugs, extrapolated from mechanism, not documented in humans ^{12Reference 12Fried LE · 2009Honokiol, a multifunctional antiangiogenic and antitumor agentView study →}.
• Glucuronidation-based metabolism. Cleared mainly by glucuronidation/sulfation, so interactions are more likely via UGT competition than CYP oxidation ^{18,19Reference 18Böhmdorfer M et al. · 2011In vitroIn vitro metabolism and disposition of honokiol in rat and human liversView study →Reference 19Jeong HU et al. · 2016AnimalComparative metabolism of honokiol in mouse, rat, dog, monkey, and human hepatocytesView study →}.
• Human isolate data are thin. Controlled human evidence is for the magnolia blend (Relora), not isolated honokiol, and long-term isolate safety is not well characterised ^{1Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →}.

Dosage

There is no established or recommended human dose for isolated honokiol. The human clinical figures that exist are for the standardised Magnolia officinalis + Phellodendron blend (Relora), not the molecule, and the mechanistic efficacy figures in the literature are preclinical rodent research doses that do not convert to human self-dosing ^{1,2Reference 1Sarrica A et al. · 2018Safety and Toxicology of Magnolol and HonokiolView study →Reference 2Qu WM et al. · 2012AnimalHonokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in miceView study →}.

Typical Forms of Human Exposure

• Magnolia bark tea, tincture or powdered bark (traditional preparations)
• Standardised magnolia-bark extracts (marketed for sleep/stress; often standardised to honokiol + magnolol)
• Proprietary magnolia + Phellodendron blends (e.g. Relora)
• Isolated / high-purity honokiol supplements
• Experimental liposomal and nanoparticle honokiol (research formulations)

These are the forms in which people encounter honokiol; the studied efficacy figures are research doses and a proprietary blend, not a personal recommendation.

References

1. Sarrica A, Kirika N, Romeo M, Salmona M, Diomede L. (2018). Safety and Toxicology of Magnolol and Honokiol. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/29925102/
2. Qu WM, Yue XF, Sun Y, et al. (2012). Honokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in mice. British Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/22537192/
3. Kuribara H, Kishi E, Hattori N, Okada M, Maruyama Y. (2000). The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark. Journal of Pharmacy and Pharmacology. https://pubmed.ncbi.nlm.nih.gov/11186252/
4. Woodbury A, Yu SP, Wei L, García P. (2013). Neuro-modulating effects of honokiol: a review. Frontiers in Neurology. https://pubmed.ncbi.nlm.nih.gov/24062717/
5. Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK. (2003). Honokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species production. Brain Research. https://pubmed.ncbi.nlm.nih.gov/14625055/
6. Liou KT, Lin SM, Huang SS, Chih CL, Tsai SK (2003). Honokiol ameliorates cerebral infarction from ischemia-reperfusion injury in rats. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/12624817/
7. Liou KT, Shen YC, Chen CF, et al. (2003). The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. European Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/12954355/
8. Li Y, Liang Z, Zhang J, et al. (2024). Neolignans in Magnolia officinalis as natural anti-Alzheimer’s disease agents: A systematic review. Ageing Research Reviews. https://pubmed.ncbi.nlm.nih.gov/38955265/
9. Qu C, Li QP, Su ZR, et al. (2022). Nano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer’s disease via inhibiting neuropathology and modulating gut microbiota. Journal of Advanced Research. https://pubmed.ncbi.nlm.nih.gov/35024199/
10. Zhang B, Wang PP, Hu KL, et al. (2019). Antidepressant-Like Effect and Mechanism of Action of Honokiol on the Mouse Lipopolysaccharide (LPS) Depression Model. Molecules. https://pubmed.ncbi.nlm.nih.gov/31141940/
11. Wang C, Gan D, Wu J, et al. (2018). Honokiol Exerts Antidepressant Effects in Rats Exposed to Chronic Unpredictable Mild Stress by Regulating Brain Derived Neurotrophic Factor Level and Hypothalamic-Pituitary-Adrenal Axis Activity. Neurochemical Research. https://pubmed.ncbi.nlm.nih.gov/29855846/
12. Fried LE, Arbiser JL. (2009). Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxidants & Redox Signaling. https://pubmed.ncbi.nlm.nih.gov/19203212/
13. Ong CP, Lee WL, Tang YQ, Yap WH. (2019). Honokiol: A Review of Its Anticancer Potential and Mechanisms. Cancers. https://pubmed.ncbi.nlm.nih.gov/31877856/
14. Lee JS, Sul JY, Park JB, et al. (2019). Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathway. International Journal of Molecular Medicine. https://pubmed.ncbi.nlm.nih.gov/30864681/
15. Zhang Y, Ren X, Shi M, et al. (2014). Downregulation of STAT3 and activation of MAPK are involved in the induction of apoptosis by HNK in glioblastoma cell line U87. Oncology Reports. https://pubmed.ncbi.nlm.nih.gov/25175884/
16. Mottaghi S, Abbaszadeh H. (2022). Natural Lignans Honokiol and Magnolol as Potential Anticarcinogenic and Anticancer Agents. A Comprehensive Mechanistic Review. Nutrition and Cancer. https://pubmed.ncbi.nlm.nih.gov/34047218/
17. Liu S, Zhang SM, Ju RJ, et al. (2017). Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. European Journal of Pharmaceutical Sciences. https://pubmed.ncbi.nlm.nih.gov/28583810/
18. Böhmdorfer M, et al. (2011). In vitro metabolism and disposition of honokiol in rat and human livers. Journal of Pharmaceutical Sciences. https://pubmed.ncbi.nlm.nih.gov/21404278/
19. Jeong HU, Kim JH, Kong TY, et al. (2016). Comparative metabolism of honokiol in mouse, rat, dog, monkey, and human hepatocytes. Archives of Pharmacal Research. https://pubmed.ncbi.nlm.nih.gov/26983827/
20. He X, Wei Y, Wang S, et al. (2022). Improved Pharmaceutical Properties of Honokiol via Salification with Meglumine: an Exception to Oft-quoted ∆pKa Rule. Pharmaceutical Research. https://pubmed.ncbi.nlm.nih.gov/35836038/
21. Liu J, Tang M, Li T, et al. (2022). Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species Inhibition. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/35264952/
22. Borgonetti V, Governa P, Manetti F, et al. (2021). A honokiol-enriched Magnolia officinalis Rehder & E.H. Wilson. bark extract possesses anxiolytic-like activity with neuroprotective effect through the modulation of CB1 receptor. Journal of Pharmacy and Pharmacology. https://pubmed.ncbi.nlm.nih.gov/33950239/

View all 22 references▾